Innovacell GmbH is focused on advancing regenerative medicine through innovative cell therapies aimed at treating fecal and urinary incontinence. Their unique approach involves the use of autologous muscle cells to regenerate the sphincter muscles responsible for these conditions. By isolating and multiplying muscle stem cells from a small sample of healthy tissue, Innovacell develops therapies that are designed to restore the functionality of weakened or damaged sphincter muscles. Their lead products, ICES13 and ICEF15, are currently in clinical development, targeting stress urinary incontinence and urge fecal incontinence, respectively. These therapies aim to provide a permanent solution through a minimally invasive procedure, potentially allowing patients to regain control and improve their quality of life.

The company operates a comprehensive platform for cell therapy development, which includes high-quality cell production, patented technologies for cell isolation, and established processes for clinical trials. Innovacell's commitment to adhering to international quality standards is evident in their proprietary production facility and their successful collaborations with regulatory bodies such as the EMA and FDA. Their research and development efforts are complemented by partnerships with academic institutions, enhancing their capabilities in translational research. Overall, Innovacell is positioned as a leader in the field of regenerative medicine, with a focus on addressing the underlying causes of incontinence through advanced cell therapy solutions.

Austria

Innovacell Biotechnologie AG is an innovative biotechnology company that develops personalized cell therapies for treatment of incontinence.

Innovacell GmbH

Company Details